drugset / Trial / NCT07335328
Fully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase 1 interventional, single-arm, open- label, treatment study designed to evaluate the safety of h20.19 CAR T cells in patients with B-cell malignancies that have failed prior therapies.
Timeline
- Start
- 2026-09-01
- Primary completion
- 2027-05-01
- Completion
- 2031-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | h20.19 CAR T cells | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | h20.19 CAR T cells | Cell therapy | 2.5e+06 cells/kg | Intravenous |